Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Chemoimmunotherapy Changes Standard Care in Stage IV Nonsquamous NSCLC

November 6th 2019

Hossein Borghaei, DO, MS, highlights pivotal trials examining chemoimmunotherapy in metastatic nonsquamous non–small cell lung cancer, ongoing research efforts, and exciting biomarkers on the horizon.

Immunotherapy Efforts Forge Ahead in Stage III NSCLC

November 5th 2019

Gregory M. M. Videtic, MD, CM, FRCPC, discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

November 4th 2019

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Dr. Mok on Overall Survival Data From the ALEX Trial in ALK+ Lung Cancer

November 1st 2019

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Chemoimmunotherapy Transforms Treatment in Nonsquamous NSCLC

November 1st 2019

Edward S. Kim, MD, discusses how the use of immunotherapy has resulted in a paradigm shift in advanced nonsquamous non–small cell lung cancer and the steps that are being taken to broaden its use in clinical practice.

Dr. Kerrigan on Remaining Challenges in ROS1+ NSCLC

October 31st 2019

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

Immunotherapy Spearheads Progress in Small Cell Lung Cancer

October 31st 2019

W. Victoria Lai, MD, discusses the impact immunotherapy has had in the management of patients with extensive-stage small cell lung cancer.

Dr. Gadgeel on the Results of the BFAST Trial in ALK+ Lung Cancer

October 31st 2019

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the results of the phase II/III BFAST trial in patients with ALK-positive lung cancer.

Therapeutic Additions Enhance ALK+ and ROS1+ Lung Cancer Paradigms

October 30th 2019

Gregory J. Riely, MD, PhD, discusses the current treatment landscape for ALK- and ROS1-positive non–small cell lung cancer.

Oncology Fellow Discusses Immunotherapy Developments in Squamous NSCLC

October 30th 2019

Pradnya D. Patil, MD, FACP, discusses the implications of these trials and the growing role of immunotherapy in lung cancer.

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

October 30th 2019

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Dr. Burns on Identifying Genetic Alterations in Lung Cancer

October 30th 2019

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.

Dr. Pennell on the Underutilization of Genetic Testing in Lung Cancer

October 30th 2019

Nathan A. Pennell, MD, PhD, discusses the underutilization of genetic testing in lung cancer.

Osimertinib Continues to Flourish as Frontline Standard in EGFR-Mutant NSCLC

October 30th 2019

Khaled A. Hassan, MD, MS, discusses the use of EGFR TKIs in the treatment of patients with advanced EGFR-mutant non–small cell lung cancer and the emergence of osimertinib as the frontline standard of care.

MRTX849 Active in KRAS G12C+ NSCLC and CRC

October 29th 2019

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLC

October 29th 2019

Nathan A. Pennell, MD, PhD, discusses the actionability of advanced ALK-positive and ROS1-positive non–small cell lung cancer and the drugs that have emerged in the frontline and second-line settings.

Durvalumab Regimens Improve PFS in Frontline Metastatic NSCLC

October 29th 2019

The addition of durvalumab (Imfinzi) to platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.

Upfront Immunotherapy Pivotal in Squamous NSCLC Paradigm

October 28th 2019

Liza C. Villaruz, MD, discusses the data with immunotherapy in squamous non–small cell lung cancer.

Dr. Segal on Next-Generation Sequencing for Lung Cancer

October 28th 2019

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.